TABLE 3.
Baseline characteristics of entire cohort
| Baseline characteristics |
All patients (N = 505) n (%) |
|---|---|
| Diagnosis | |
| Brain Metastasis | 164 (32.5) |
| Bone Metastasis | 253 (50.1) |
| Other | 88 (17.4) |
| Treatment recommendation | |
| None | 24 (4.8) |
| SFRT (1 Fx) | 41 (8.1) |
| SCRT (2‐9 Fxs) | 82 (16.2) |
| LCRT (≥10 Fxs) | 304 (60.2) |
| SAbR | 54 (10.7) |
| Age (y) | |
| ≤67 | 259 (51.3) |
| >67 | 246 (48.7) |
| Race | |
| Caucasian | 457 (90.5) |
| African‐American | 40 (7.9) |
| Other/Unknown | 8 (1.6) |
| Ethnicity | |
| Non‐Hispanic or Latino | 492 (97.4) |
| Other/Unknown | 13 (2.6) |
| Sex | |
| Male | 266 (52.7) |
| Female | 239 (47.3) |
| Practice setting | |
| Community | 309 (61.2) |
| Academic | 196 (38.8) |
| Primary site | |
| Lung | 261 (51.7) |
| Breast | 55 (10.9) |
| Prostate | 32 (6.3) |
| Other | 157 (31.1) |
| Performance status | |
| 90‐100, ECOG 0 | 42 (8.3) |
| 70‐80, ECOG 1 | 192 (38.0) |
| 50‐60, ECOG 2 | 171 (33.9) |
| 30‐40, ECOG 3 | 48 (9.5) |
| 10‐20, ECOG 4 | 7 (1.4) |
| Unrecorded | 45 (8.9) |
| Inpatient consult | |
| No | 371 (73.5) |
| Yes | 134 (26.5) |
| Time of death (d) | |
| Within 0‐30 | 193 (38.2) |
| Within 31‐60 | 28 (5.5) |
| Within 61‐90 | 284 (56.2) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; LCRT, Long‐course Radiotherapy; SAbR, Stereotactic Ablative Radiotherapy; SCRT, Short‐course Radiotherapy; SFRT, Single‐fraction Radiotherapy. [Correction added on 22 July 2020, after first online publication: The data under subheading 'Practice setting' and 'Performance status' have been corrected, and the subheading 'Inpatient consult' has been added in this version]